


Providing patients greater access to clinical trials and precision medicine through molecular tumor boards

navify Tumor Board to enhance Gyn cancer treatments

Gynecological cancers are one of the leading causes of cancer related deaths in women worldwide.¹ In Italy, a cooperative group of oncology specialists – the Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) – is engaging a molecular tumor board using **navify** Tumor Board to improve collaboration among its members, enabling timely review of clinical and molecular data from patients and facilitating matches with the newest available medicines and clinical trials.



Situation

In gynecologic oncology, molecular biomarkers are relatively limited, so molecular data are sometimes complex and are often interpreted on a case-by-case basis. The result may be delays in decision making or suboptimal treatment where patients may not have access to the growing number of new innovative drugs and clinical trials designed to treat cancers with specific genetic alterations.

Case Study

Solution

Beginning in June 2021, MITO inaugurated a fully virtual, nationwide molecular tumor board using **navify** Tumor Board as the operational platform. This initiative includes about 40 MITO centers participating in the GYNGER observational trial (GYNecological cancers GENetic profile Registry) and related specialists from oncology, gynecology, pathology, molecular biology, genetics and study coordinators of each center.

Results

Using **navify** Tumor Board, 50 participating specialists who faced gynecological cancer patients are able to access, review and share anonymized clinical cases. The board's final decision may include ranking of a molecular alteration and a matching drug using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), or patient referral to a bio-marker driven trial or expanded access program that is active in Italy. Finally, the patient is enrolled into the GYNGER study. In summary, **navify** Tumor Board is demonstrating its effectiveness at helping geographically dispersed multidisciplinary teams to collaborate more closely to deliver targeted and personalized patient care through expanded access to bio-marker specific treatment.

“Molecular tumor boards can play a pivotal role in spreading new concepts of cancer genomics, flattening the learning curve of precision medicine.”

Prof. Sandro Pignata

Department of Urology and Gynecology Director, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy

(Source: A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group)

Learn more

www.navify.com/products/navify-tumor-board

¹Pahwa, Sangeeta, and Arshdeep Kaur. “Statistical analysis of gynecological cancer.” *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*, vol. 11, no. 1, Jan. 2022, pp. 130+. *Gale Academic OneFile*, link.gale.com/apps/doc/A690697383/AONE?u=anon-e374988c&sid=googleScholar&xid=eaf8d0d6. Accessed 26 Apr. 2022.